Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Antimicrobial Resistance Diagnostic Research Report 2026: Markets, Strategies, Trends and Forecasts 2025-2029 by Pathogen and Technology with Executive Guides and Customization

globenewswire.com
BIOX Listed as a player in the dynamic market for antimicrobial resistance diagnostics. No specific performance indicators or news provided. MRNA While not explicitly mentioned, the context of new diagnostic technologies and treatments for infectious diseases could indirectly relate to companies in the mRNA vaccine space. However, no direct link is made in the article. PFE Mentioned as partnering with BD to study AMR Dx. This indicates collaboration in the field but doesn't provide specific sentiment on Pfizer's performance or outlook. TMO Listed as a key company in the AMR diagnostics space. The article provides a market overview and does not offer specific sentiment on Thermo Fisher. ILMN Mentioned for building NGS-based respiratory panels with IDbyDNA. This points to activity in the diagnostics field but lacks specific sentiment. QGEN Listed as a key company in the antimicrobial resistance diagnostics market. The article provides a market overview and does not offer specific sentiment on Qiagen. DGX While not explicitly mentioned, Quest Diagnostics is a major player in the diagnostics industry. The article discusses the growing market for diagnostics, which could be seen as a generally positive backdrop, but no direct sentiment is expressed. ABT Listed as a key company in the AMR diagnostics market. The article provides a market overview and does not offer specific sentiment on Abbott Laboratories. BDX Mentioned for partnering with Pfizer and Wellcome to study AMR Dx. This indicates involvement in the field but doesn't provide specific sentiment on BDX's performance or outlook. HOLX Mentioned for its planned acquisition of Mobidiag. This suggests strategic expansion in the diagnostics sector, but the sentiment is neutral as it's a factual announcement. EXAS While not explicitly mentioned, Exact Sciences is a prominent diagnostics company. The article's focus on the growing diagnostics market provides a generally positive context, but no direct sentiment is expressed towards Exact Sciences. DHR Mentioned as the parent company of Cepheid. The article lists Cepheid as a player in the AMR diagnostics market, implying Danaher's involvement through its subsidiary.

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization" report has been added to ResearchAndMarkets.com's offering.

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics come along? New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market.

The publisher has looked at the technology picture, giving you a plain language understanding of the different ways pathogens, and infections can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile over 30 companies, large and small, working in this area.

Key Topics Covered:

1 Market Guides

1.1 Antimicrobial Resistance - Strategic Situation Analysis

1.2 Guide for Executives and Business Development Staff

1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

2.1 The Threat and Opportunity of Antimicrobial Resistance

2.2 Defining the Opportunity

2.2.1 Revenue Market Size

2.3 Methods and Sources

2.3.1 Methodology

2.3.2 Sources

2.3.3 Authors

2.4 Perspective: Healthcare and the IVD Industry

2.4.1 Global Healthcare Spending

2.5 Spending on Diagnostics

2.5.1 Important Role of Insurance for Diagnostics

3 Overview of a Dynamic Market

3.1 Players in a Dynamic Market

3.1.1 Diagnostic Test Developer

3.1.2 Instrumentation Supplier

3.1.3 Chemical/Reagent Supplier

3.1.4 Pathology Supplier

3.1.5 Independent Clinical Laboratory

3.1.6 Public National/regional Laboratory

3.1.7 Hospital Laboratory

3.1.8 Physicians Office Lab (POLS)

3.1.9 Audit Body

3.1.10 Certification Body

3.2 Understanding Antimicrobial Resistance

3.2.1 What is Antimicrobial Resistance (AMR)

3.2.2 Bacteria and Other Microbes

3.2.3 The History of Antibiotics

3.2.4 The Role of Animal Husbandry

3.2.5 The Implications of Horizontal Transfer

3.2.6 The Threat of AMR

3.3 The Changing Road to New Antibiotics & Technologies

3.4 The Key Role of Diagnostics in AMR

4 The Market Opportunity of AMR

4.1 The Key Large Market Opportunities in AMR

4.1.1 Streptococcus Pneumoniae (DRSP)

4.1.2 Campylobacter (DRC)

4.1.3 Clostridium Difficile (CD)

4.1.4 Staphylococcus aureus (MRSA)

4.1.5 Neisseria gonorrhoeae (DRNG)

4.1.6 Salmonella (DRNTS)

4.2 Diagnostic Technology Development Opportunities

4.2.1 What's Wrong with Microbiology

4.2.2 The Features Battleground of Infectious Disease Diagnostics

4.2.3 Multiplex vs. POC/Rapid

4.2.4 The Miracle of Genetics

4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation

4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.

4.2.7 Markers of Resistance.

4.2.8 What Happens to the Microbiology Lab?

5 Antibiotic Resistance Diagnostics Recent Developments

5.1 Antibiotic Resistance Recent Developments

5.1.1 Importance of These Developments

5.1.2 How to Use This Section

5.2 FDA Clears New bioMerieux Diagnostic System and Panel

5.3 Selux Diagnostics Phenotyping System Gets FDA Approval

5.4 New diagnostics to tackle drug resistant infections

5.5 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels

5.6 Three companies join forces to tackle antimicrobial resistance (AMR)

5.7 T2 Biosystems Exercises BARDA Option

5.8 OpGen to Ramp up Use of Acuitas AMR Gene Panel

5.9 BD Partners With Pfizer, Wellcome to Study AMR Dx

5.10 Sepsis Test Developers Accelerate Plans

5.11 OpGen Receives FDA Clearance for AMR Panel

5.12 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs

5.13 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery

5.14 BioMerieux Receives CE Mark for Vitek Clinical Microbiology System

5.15 Hologic to Acquire Mobidiag

5.16 Campylobacter strains exchange genes

5.17 Disinfection spreads antimicrobial resistance

5.18 Molzym, Fraunhofer Developing Rapid Sepsis Dx

5.19 Illumina, IDbyDNA Build NGS-Based Respiratory Panel

5.20 Accelerate Diagnostics Expands AMR Testing

5.21 Rapid diagnostics linked to optimal antibiotics

5.22 Visby Medical Wins AMR Diagnostic Competition

5.23 DNAe Technology SARS-CoV-2 Sequences

5.24 Infections with foodborne bacteria becoming harder to treat

5.25 Dust is sharing antibiotic resistance genes

6 Key AMR Diagnostics Companies

6.1 1928 Diagnostics

6.2 Abacus Diagnostica

6.3 Abbott Laboratories

6.4 Accelerate Diagnostics

6.5 ADT Biotech

6.6 Beckman Coulter Diagnostics

6.7 Becton, Dickinson and Company

6.8 Binx Health

6.9 bioMerieux Diagnostics

6.10 Bio-Rad Laboratories, Inc.

6.11 Cepheid (Danaher)

6.12 Curetis N.V. / Curetis GmbH

6.13 Day Zero Diagnostics.

6.14 Enzo Biochem

6.15 Eurofins Scientific

6.16 Fusion Genomics.

6.17 GeneFluidics

6.18 Genetic Signatures

6.19 Great Basin Corporation

6.20 Hologic

6.21 Hutman Diagnostics

6.22 Inflammatix

6.23 Linear Diagnostics.

6.24 Lumos Diagnostics

6.25 Millipore Sigma

6.26 OpGen

6.27 Ortho Clinical Diagnostics

6.28 Perkin Elmer

6.29 Qiagen

6.30 Roche Molecular Diagnostics

6.31 SeLux Diagnostics

6.32 Sense Biodetection

6.33 Siemens Healthineers

6.34 Sysmex

6.35 Thermo Fisher Scientific Inc.

6.36 Visby Medical

7 The Global Market for Antimicrobial Resistance Diagnostics

7.1 Global Market Overview by Country

7.2 Global Market by Technology - Overview

7.3 Global Market by Technology - Overview

8 Global Antibiotic Resistance Diagnostic Markets - By Pathogen

8.1 Drug Resistant Streptococcus Pneumoniae - DRSP

8.2 Drug Resistant Campylobacter - DRC

8.4 Methicillin Resistant Staphylococcus Aureus - MRSA

8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG

8.6 Drug Resistant Salmonella - DRNTS

9 Global Antibiotic Resistance Diagnostic Markets - by Technology

9.1 Microbiology Culture

9.2 Immunoassay

9.3 PCR

9.4 NGS

9.5 Mass Spectrometry - MS

9.6 Rapid and Point of Care - Rapid/POC

10 Vision of the Future of AMR Diagnostics

11 Appendices

11.1 United States Medicare System: Clinical Laboratory Fees Schedule

For more information about this report visit https://www.researchandmarkets.com/r/ngor8t

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.